CureVac NV (CVAC)
3.89
+0.12
(+3.18%)
USD |
NASDAQ |
May 31, 16:00
3.88
-0.01
(-0.26%)
After-Hours: 20:00
CureVac Cash from Operations (Quarterly): -104.88M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -104.88M |
| December 31, 2023 | -45.82M |
| September 30, 2023 | -65.69M |
| June 30, 2023 | -71.55M |
| March 31, 2023 | -106.96M |
| December 31, 2022 | -62.96M |
| September 30, 2022 | -24.55M |
| June 30, 2022 | -61.10M |
| Date | Value |
|---|---|
| March 31, 2022 | -153.18M |
| December 31, 2021 | -218.87M |
| September 30, 2021 | -317.25M |
| June 30, 2021 | -94.51M |
| March 31, 2021 | -236.79M |
| March 31, 2020 | -2.958M |
| March 31, 2019 | -25.71M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-317.25M
Minimum
Sep 2021
-2.958M
Maximum
Mar 2020
-111.93M
Average
-83.03M
Median
Cash from Operations (Quarterly) Benchmarks
| BioNTech SE | -344.65M |
| Affimed NV | -27.02M |
| InflaRx NV | -16.15M |
| MorphoSys AG | -- |
| Immatics NV | -35.42M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -5.527M |
| Cash from Financing (Quarterly) | -1.221M |
| Free Cash Flow | -339.08M |
| Free Cash Flow Per Share (Quarterly) | -0.4922 |
| Free Cash Flow to Equity (Quarterly) | -110.40M |
| Free Cash Flow to Firm (Quarterly) | -110.40M |
| Free Cash Flow Yield | -38.91% |